UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Enliven Therapeutics, Inc. $ELVN

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 18.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 80,072 shares of the company’s stock after acquiring an additional 12,597 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.11% of Enliven Therapeutics worth $4,064,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Enliven Therapeutics during the second quarter worth $221,255,000. Vestal Point Capital LP grew its position in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the period. Siren L.L.C. acquired a new stake in Enliven Therapeutics in the 1st quarter worth about $29,252,000. Jupiter Topco LLC acquired a new stake in Enliven Therapeutics in the 2nd quarter worth about $30,617,000. Finally, Affinity Asset Advisors LLC purchased a new stake in Enliven Therapeutics during the 1st quarter worth approximately $23,007,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Trading Down 3.2%

ELVN stock opened at $57.45 on Thursday. The company has a market cap of $4.21 billion, a price-to-earnings ratio of -34.40 and a beta of 0.30. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The firm has a 50-day moving average of $56.18 and a two-hundred day moving average of $45.00.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ELVN. JonesTrading raised their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. HC Wainwright boosted their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Guggenheim reduced their price objective on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. William Blair initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating for the company. Finally, Mizuho raised their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Insider Buying and Selling

In related news, Director Mika Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the transaction, the director owned 87,373 shares in the company, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Kunkel sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director directly owned 41,884 shares in the company, valued at $2,114,723.16. This trade represents a 19.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 186,849 shares of company stock worth $10,998,857. 3.00% of the stock is owned by corporate insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.